Immunofluorescence Assay Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

The Report Covers Immunofluorescence Assay Market Analysis and it is Segmented by Product (Reagents and Kits, Instruments, Consumables & Accessories), Type (Indirect Immunofluorescence, and Direct Immunofluorescence), Application (Cancer, Infectious Diseases, Autoimmune Diseases, and Others), and Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The Market values are Provided in (USD million) for the above segments.

Immunofluorescence Assay Market Size

Single User License


Team License


Corporate License


Book before:
Immunofluorescence Assay Market Analysis
Study Period 2019 - 2029
Base Year For Estimation 2023
CAGR 5.80 %
Fastest Growing Market Asia Pacific
Largest Market North America
Market Concentration Medium

Major Players

Global Immunofluorescence Assay Market

*Disclaimer: Major Players sorted in no particular order


Need a report that reflects how COVID-19 has impacted this market and its growth?

Single User License


Team License


Corporate License


Book before:

Immunofluorescence Assay Market Analysis

The Immunofluorescence Assay market studied was projected to grow with a CAGR of 5.8% over the forecast period.

The studied market was impacted by the pandemic. The SARS-CoV-2 outbreak emerged as a potential opportunity for the market's growth. Several research organizations and biopharmaceutical companies are evaluating immunofluorescence assay to develop it as an effective diagnostic tool. The article 'A Novel Immunofluorescence Assay for the rapid serological detection of SARS-CoV-2 infection' published in April 2021, mentions the design of a cell-based fluorescent serology assay to detect SARS-CoV-2 infection. The assay is based on the capture of IgG antibodies in the serum of COVID-19-positive patients using cells exogenously expressing SARS-COV-2 spike and their subsequent fluorescent detection. Such novel immunofluorescent assays implemented to detect COVID-19 infections are expected to impact the growth of the market studied. Also, the article titled 'Rapid Lateral flow immunoassay for the fluorescence detection of SARS-CoV-2 RNA' published in December 2020 mentioned that amplification-free nucleic acid immunoassay, implemented on a lateral flow strip for the fluorescence detection of SARS-CoV-2, achieved sensitivities of 100% and specificities of 99% for both types of throat and sputum samples of COVID-19. The article titled 'Evaluating the serological status of COVID-19 patients using an indirect immunofluorescent assay, France' published in May 2020 mentioned that the immunofluorescence assay is useful for monitoring SARS-CoV-2 exposure at the individual and population levels. The effectiveness of these assays for detecting COVID-19 infection is expected to impact the growth of the market studied. Thus, the market was adversely impacted during the initial phase of the pandemic however, its advantages to diagnose COVID are expected to increase its growth during the upcoming period.

The major factor attributing to the growth of the market is the increase in the incidence of disease. Cancer is a major chronic disease in regions such as the Americas, Asia, and Europe. As further research and development activities are being conducted in the area with huge funding from the government, the market studied is expected to grow significantly over time. For instance, as per the Joint Research Commission's report of European Commission released in July 2020, it was estimated that in 2020 about 2.7 million (excluding non-melanoma cancer) new cancer cases would be diagnosed in the European Union, and breast cancer will be the most prevalent form of cancer with about 355,000 new cases in 2020. These conditions of chronic kidney disorders increase the demand for immunofluorescence assay. The American Cancer Society's estimates for primary liver cancer and intrahepatic bile duct cancer in the United States for 2020 include about 42,810 new cases (30,170 in men and 12,640 in women) diagnosed. According to the study published in Clinical Infectious Diseases, titled 'Re-emergence of Invasive Pneumococcal Disease (IPD) in Germany during the Spring and Summer of 2021' in February 2022, in April 2021, IPD levels in children aged 0 to 4 years old began to rebound to baseline levels. By June 2021, they had surpassed them (a 9 percent increase over the average monthly values for 2015-2019). IPD cases increased beyond baseline values in children 5 to 14, adults 15-34, and people 80 years and older beginning in July 2021, with increases, also beginning in Spring 2021. Such prevalence of infectious diseases is expected to drive the growth of the market studied.

Similarly, initiatives by market players are another factor in market growth. In September 2022, in order to enable subcellular spatial multi-omics measurement with the simultaneous detection of RNA and proteins during a typical MERFISH experiment, Vizgen introduced the MERSCOPE Protein Co-detection Kit. With its oligo conjugated antibodies, the MERSCOPE Protein Stain Reagent Kit enhances the detection of primary antibodies that are directed at proteins and provides high-quality protein staining that is comparable to protein immunofluorescence staining. Thus, the abovementioned factors are expected to increase the market growth.

However, the gaining popularity of the alternative procedures is the major drawback of the market growth

Immunofluorescence Assay Market Trends

This section covers the major market trends shaping the Immunofluorescence Assay Market according to our research experts:

Instruments Segment is Expected to Hold a Significant Market Share Over the Forecast Period

The instruments segment encompasses the apparatus or devices used alone or in combination and intended by the manufacturer for the in vitro examination of specimens derived from the human body, solely to provide information for diagnostic or compatibility purposes. The rising prevalence of chronic and infectious diseases among people is expected to further propel market growth. Immunofluorescence assay instruments are used to detect health and disease state markers. The most widely used clinical diagnostic instruments are chemistry analyzers, immunoassay analyzers, hematology analyzers, centrifuges, microscopes, imaging analysis systems, slide processing systems, and other analytical instruments. The primary growth drivers of the segment include the increasing adoption of point-of-care and multi-test platforms. Immunofluorescence assay testing using multi-test platforms has the advantage of allowing multiple markers to be detected simultaneously. An increasing number of product launches have helped boost the market growth. In September 2020, CTK launched its latest system, CTK's RaFIA System, for rapid quantitative tests. This quantitative system is easy to use while offering a high level of sensitivity and a broad working range. Also, in March 2021, EUROIMMUN, a PerkinElmer Inc. company, launched the EUROPatternTM Microscope Live (EPML), a compact immunofluorescence microscope with the fourth generation of the company's well-established EUROLabOfficeTM 4.0 (ELO 4.0) laboratory management program. Hence, owing to the above-mentioned developments in the market coupled with the increasing adoption of these devices, the segment is expected to witness high growth.

Thus, due to the above-mentioned factors, the segment is expected to witness significant growth over the forecast period.


North America is Expected to Dominate the Market Over the Forecast Period

North America is expected to dominate the overall market, throughout the forecast period. The market growth is due to factors such as the presence of key players, the high prevalence of diseases in the region, and established healthcare infrastructure are some of the key factors accountable for its large share in the market. According to Organization for Economic Co-Operation and Development (OECD) figures, there were 17,149 coronary artery bypass graft surgeries performed in 2020 in Canada. Similarly, as per the data from the American Heart Association 2022, in Mexico, 56.1% of adults have high levels of LDL-C, or bad cholesterol, which is thought to be the primary risk factor for cardiovascular disease. Similarly, the growing demand for effective diagnostic solutions to obtain proper treatment for chronic diseases is also expected to drive the growth of the market in the United States. For instance, in the Cancer Facts & Figures 2022 data published by the American Cancer Society, an estimated 1.9 million new cancer cases were diagnosed. Hence, the prevalence of chronic diseases in the region is anticipated to create more opportunities for the development of immunofluorescence assays during the forecast period. Initiatives by market players in the region are another factor in market growth. In July 2020, Ultivue Inc., a United States-based company, and OracleBio entered a collaboration to accelerate personalized tumor characterization for drug research and development in translational and clinical oncology with the application of multiplex immunofluorescence staining and imaging.

Thus, due to the above-mentioned factors, the market is expected to witness significant growth over the forecast period.


Immunofluorescence Assay Industry Overview

The Immunofluorescence Assay market is moderately competitive and consists of several major players. Some of the companies which are currently dominating the market are Thermo Fisher, Werfen, Bio-Rad Laboratories, Inc., Abcam, PerkinElmer Inc., Merck Millipore, Cell Signaling Technology, Sino Biological, Danaher.

Immunofluorescence Assay Market Leaders

  1. Thermo Fisher

  2. Bio-Rad Laboratories, Inc.

  3. Abcam

  4. PerkinElmer Inc.

  5. Werfen

*Disclaimer: Major Players sorted in no particular order

Need More Details on Market Players and Competitors?
Download PDF

Immunofluorescence Assay Market News

  • In September 2022, Propath UK and Nucleai collaborated to develop and validate a 30-plex immunofluorescence panel focused on protein targets relevant to immuno-oncology.
  • In January 2022, Thermo Fisher Scientific Inc. acquired PeproTech for a total cash purchase of approximately USD 1.85 billion. The company products included various ELISA immnunoflourence kits.

Immunofluorescence Assay Market Report - Table of Contents


    1. 1.1 Study Assumptions and Market Defintion

    2. 1.2 Scope of the Study




    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing Incidence of Cancer and Other Infectious Diseases

      2. 4.2.2 Growing Investments By Government and Non-government Organizations

    3. 4.3 Market Restraints

      1. 4.3.1 Upsurge of Alternative Tests Which are More Effective

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION (Market Size by Value - USD million)

    1. 5.1 By Product

      1. 5.1.1 Reagents and Kits

      2. 5.1.2 Instruments

      3. 5.1.3 Consumables & Accessories

    2. 5.2 By Type

      1. 5.2.1 Indirect Immunofluorescence

      2. 5.2.2 Direct Immunofluorescence

    3. 5.3 By Application

      1. 5.3.1 Cancer

      2. 5.3.2 Infectious Diseases

      3. 5.3.3 Autoimmune Diseases

      4. 5.3.4 Others

    4. 5.4 Geography

      1. 5.4.1 North America

        1. United States

        2. Canada

        3. Mexico

      2. 5.4.2 Europe

        1. Germany

        2. United Kingdom

        3. France

        4. Italy

        5. Spain

        6. Rest of Europe

      3. 5.4.3 Asia-Pacific

        1. China

        2. Japan

        3. India

        4. Australia

        5. South Korea

        6. Rest of Asia-Pacific

      4. 5.4.4 Middle East and Africa

        1. GCC

        2. South Africa

        3. Rest of Middle East and Africa

      5. 5.4.5 South America

        1. Brazil

        2. Argentina

        3. Rest of South America


    1. 6.1 Company Profiles

      1. 6.1.1 Abcam

      2. 6.1.2 Becton, Dickinson and Company

      3. 6.1.3 Bio-Rad Laboratories, Inc.

      4. 6.1.4 Cell Signaling Technology

      5. 6.1.5 Danaher Corporation

      6. 6.1.6 Enzo Life Sciences, Inc.

      7. 6.1.7 Werfen

      8. 6.1.8 Merck Millipore (Merck KGaA)

      9. 6.1.9 PerkinElmer Inc.

      10. 6.1.10 Sino Biological

      11. 6.1.11 Thermo Fisher Scientific Inc.

    2. *List Not Exhaustive

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Immunofluorescence Assay Industry Segmentation

As per the scope of the report, immunofluorescence is the specific antigen and antibody reaction where the antibodies are labeled with a fluorescent dye, and the antigen-antibody complex is visualized using a fluorescent microscope. This immunochemical technique allows the detection and localization of a wide variety of antigens in different types of tissues of various cell preparations. The immunofluorescence assay market is segmented by product (reagents and kits, instruments, consumables & accessories), type (indirect immunofluorescence, and direct immunofluorescence), application (cancer, infectious diseases, autoimmune diseases, and others), and geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across the major regions globally. The report offers the values (USD million) for the above segments.

By Product
Reagents and Kits
Consumables & Accessories
By Type
Indirect Immunofluorescence
Direct Immunofluorescence
By Application
Infectious Diseases
Autoimmune Diseases
North America
United States
United Kingdom
Rest of Europe
South Korea
Rest of Asia-Pacific
Middle East and Africa
South Africa
Rest of Middle East and Africa
South America
Rest of South America
Need A Different Region Or Segment?
Customize Now

Immunofluorescence Assay Market Research FAQs

The Global Immunofluorescence Assay Market is projected to register a CAGR of 5.80% during the forecast period (2024-2029)

Thermo Fisher, Bio-Rad Laboratories, Inc., Abcam, PerkinElmer Inc. and Werfen are the major companies operating in the Global Immunofluorescence Assay Market.

Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).

In 2024, the North America accounts for the largest market share in Global Immunofluorescence Assay Market.

The report covers the Global Immunofluorescence Assay Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Global Immunofluorescence Assay Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.

Immunofluorescence Assay Industry Report

Statistics for the 2023 Immunofluorescence Assay market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Immunofluorescence Assay analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!

Immunofluorescence Assay Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)